Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

PURPOSE: We present long-term outcomes from 2 randomized studies [STAMP (with abiraterone, NCT01487863) and STRIDE (with enzalutamide, NCT01981122)] that were performed to study the impact of sequential or concurrent administration of androgen receptor–targeting agents (ARTAs) on sipuleucel-T immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonarakis, Emmanuel S., Subudhi, Sumit K., Pieczonka, Christopher M., Karsh, Lawrence I., Quinn, David I., Hafron, Jason M., Wilfehrt, Helen M., Harmon, Matthew, Sheikh, Nadeem A., Shore, Neal D., Petrylak, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320463/
https://www.ncbi.nlm.nih.gov/pubmed/37058234
http://dx.doi.org/10.1158/1078-0432.CCR-22-3832

Ejemplares similares

Ejemplares similares